- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05411666
Maintenance Optimization of the Fully Implanted Venous Catheter (OTIMACAT)
Central venous catheter (CVC) are intravascular devices used in clinical practice, namely to administer fluid therapy, parenteral nutrition, drugs, blood products, hemodynamic monitoring, also being a gateway to the collection of blood samples or laboratory monitoring.
The fully implanted central venous catheter (CVCTI) is a type of central venous access surgically placed, which is characterized by containing a subcutaneous reservoir that is accessed by puncturing the camera with a blunt needle, widely used in cancer patients. The fully implanted central venous catheter is recommended when there is a need for intermittent vascular access and of long duration.
The maintenance of the CVCTI, as it's the necessity, frequency, and method is subject of some controversy, with discrepancies between the various cancer centers and guidance documents, once they occur several different intervals and maintenance methods.
The objective of this study is to assess the necessity of frequent maintenance of fully implanted central venous catheter, still assuring its viability and holding the same or lower number incidence of complications.
Participants in this study are cancer patients with a CVC fully implanted for chemotherapy, in follow-up phase. Participants will be randomized in one of two arms: Maintenance with saline solution and no maintenance.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rosana Magalhaes
- Phone Number: +351 253 027 249
- Email: cro@ccabraga.org
Study Locations
-
-
-
Braga, Portugal, 4710-243
- Recruiting
- Serviço de Hospital de Dia, Hospital de Braga
-
Contact:
- Rosana Magalhaes
- Phone Number: 00351 253 027249
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients over 18 years of age.
- Cancer patients, undergoing placement of CVCTI for chemotherapy, in follow-up, who finished chemotherapy up to a maximum period of 10 weeks.
- Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
- Evidence of signed and dated informed consent indicating that the patient has been informed of all relevant aspects of the study and agrees to participate.
Exclusion Criteria:
- Presence of metastases or any other condition that may be an indication for intravenous treatments or additional chemotherapy regimens
- History of CVCTI-related adverse events during the treatment phase
- Patients on anticoagulant medication
- History of thrombophilia
- Pregnancy/Breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Arm 1
Saline solution maintenance of the Central venous catheter (CVC)
|
Saline solution maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B|Braun, according to local standard procedures.
Other Names:
|
Experimental: Arm 2
No maintenance of the Central venous catheter (CVC)
|
No maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B|Braun.
Just visual inspection to local site of CVC insertion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Adverse Events
Time Frame: Time since screening until follow-up visit (on average 20 months)
|
The occurrence of any adverse event related to the use of the CVCTI, thus allowing to assess the difference between the 2 groups with as much data as possible.
|
Time since screening until follow-up visit (on average 20 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurence of AE related with infectious complications
Time Frame: Time since screening until follow-up visit (on average 20 months)
|
The occurrence of adverse events related to infectious complications in the 2 groups.
|
Time since screening until follow-up visit (on average 20 months)
|
Occurence of AE related with thrombotic complications
Time Frame: Time since screening until follow-up visit (on average 20 months)
|
The occurrence of adverse events related to thrombotic complications of both CVCTI and venous thrombosis in both groups.
|
Time since screening until follow-up visit (on average 20 months)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ema Alves, Serviço de Hospital de Dia, Hospital de Braga, EPE
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OTIMACAT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Saline solution maintenance of the CVC
-
University of CagliariNot yet recruiting
-
Núria Santaularia CapdevilaInstitut Català de la SalutCompletedMyocardial Ischemia | Physical ExerciseSpain
-
Hospital General Universitario ElcheCompleted
-
Federal University of Minas GeraisNot yet recruitingAnesthesia, ConductionBrazil
-
University of CalgaryMedical University of South Carolina; University of Colorado, Denver; The Hospital... and other collaboratorsRecruitingHemolytic-Uremic Syndrome | Shiga Toxin-Producing Escherichia Coli (E. Coli) InfectionUnited States, Canada
-
Federal University of UberlandiaUnknown
-
Grünenthal GmbHJohnson & Johnson Pharmaceutical Research & Development, L.L.C.TerminatedPain | Cancer | NeoplasmUnited States, Argentina, Chile, France, Latvia, Ukraine
-
Alejandro Lizaur-Utrilla, PhD, MDUniversity of AlicanteCompletedAnemia | Hip FracturesSpain
-
Maastricht University Medical CenterKU LeuvenCompletedGastrointestinal Diseases | Dyspepsia | Irritable Bowel Syndrome | Colonic Diseases, Functional | Abdominal Pain | Visceral PainNetherlands